Nigel McCracken
Chief Tech/Sci/R&D Officer chez BERGENBIO ASA
Profil
Nigel McCracken is currently the Chief Scientific Officer at BerGenBio ASA and the Chief Operating Officer at Virax Biolabs Group Ltd.
He previously worked as the Executive Director & VP-Translational Medicine at Debiopharm International SA from 2014 to 2019.
He also held a position as COO and Senior VP-Discovery & Early Development at NuCana Plc.
Dr. McCracken received his undergraduate degree from the University of Strathclyde and his graduate degree from King's College London.
Postes actifs de Nigel McCracken
| Sociétés | Poste | Début |
|---|---|---|
| BERGENBIO ASA | Chief Tech/Sci/R&D Officer | 01/01/2021 |
| VIRAX BIOLABS GROUP LIMITED | Chief Operating Officer | 01/09/2023 |
Anciens postes connus de Nigel McCracken
| Sociétés | Poste | Fin |
|---|---|---|
Debiopharm International SA
 Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Director/Board Member | 01/04/2019 |
| NUCANA PLC | Chief Operating Officer | - |
Formation de Nigel McCracken
| University of Strathclyde | Undergraduate Degree |
| King's College London | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| BERGENBIO ASA | Health Technology |
| NUCANA PLC | Health Technology |
| VIRAX BIOLABS GROUP LIMITED | Finance |
| Entreprise privées | 1 |
|---|---|
Debiopharm International SA
Debiopharm International SA Pharmaceuticals: MajorHealth Technology Debiopharm International SA operates as a biopharmaceutical development company with focus on biologics and drug evaluation, licensing and development. It formulates and develops products for the treatment of cancer, endometriosis, uterine fibroids and hepatitis. The company was founded in 1979 and is headquartered in Lausanne, Switzerland. | Health Technology |
